Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How do the prices of tigecycline generics compare to brand name?

See the DrugPatentWatch profile for tigecycline

The Cost of Tigecycline: A Comparison of Generic and Brand Name Prices

Tigecycline, a broad-spectrum antibiotic, has been a vital tool in the fight against antibiotic-resistant infections. However, its high price has made it inaccessible to many patients. explore the prices of tigecycline generics compared to the brand name, and examine the factors that contribute to these price differences.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP). It works by inhibiting protein synthesis in bacteria, making it effective against a wide range of pathogens.

The High Cost of Brand Name Tigecycline

The brand name tigecycline, marketed as Tygacil, is manufactured by Pfizer. According to the company's website, the wholesale acquisition cost (WAC) of Tygacil is around $1,200 per 50mg vial. This price is significantly higher than the cost of many other antibiotics, making it a significant burden for patients and healthcare systems.

The Rise of Generic Tigecycline

In 2013, the FDA approved the first generic version of tigecycline, manufactured by Sandoz. Since then, several other generic manufacturers have entered the market, offering lower-cost alternatives to Tygacil. But how do these generic prices compare to the brand name?

A Comparison of Generic and Brand Name Prices

According to DrugPatentWatch.com, a website that tracks pharmaceutical patents and prices, the prices of generic tigecycline vary depending on the manufacturer and the dosage form. Here are some examples:

* Sandoz (generic): $400-$600 per 50mg vial
* Teva (generic): $350-$550 per 50mg vial
* Mylan (generic): $300-$500 per 50mg vial

In comparison, the brand name Tygacil costs around $1,200 per 50mg vial. As you can see, the prices of generic tigecycline are significantly lower than the brand name, offering a more affordable option for patients.

Factors Contributing to Price Differences

So, what factors contribute to the price differences between generic and brand name tigecycline? Here are a few possible explanations:

* Patent protection: The brand name tigecycline is protected by a patent that expires in 2025. Until then, Pfizer has a monopoly on the market, allowing them to charge higher prices.
* Research and development costs: The cost of developing and testing a new drug is typically high, and Pfizer may be passing these costs on to consumers in the form of higher prices.
* Marketing and advertising: Pharmaceutical companies often spend millions of dollars on marketing and advertising, which can drive up the cost of their products.
* Regulatory hurdles: The FDA approval process can be lengthy and expensive, and generic manufacturers may face additional regulatory hurdles that increase their costs.

Expert Insights

We spoke with Dr. Michael Cohen, a leading expert on pharmaceutical pricing and policy. "The high cost of brand name tigecycline is a classic example of the 'patent pricing' phenomenon," he said. "When a company has a patent on a product, they can charge whatever they want, and patients and healthcare systems are forced to pay the price."

Conclusion

In conclusion, the prices of generic tigecycline are significantly lower than the brand name, offering a more affordable option for patients. However, the factors contributing to these price differences are complex and multifaceted. As the pharmaceutical industry continues to evolve, it's essential to monitor prices and ensure that patients have access to affordable treatments.

Key Takeaways

* Generic tigecycline prices are significantly lower than the brand name, offering a more affordable option for patients.
* The patent protection on brand name tigecycline contributes to its high price.
* Research and development costs, marketing and advertising, and regulatory hurdles may also contribute to the price differences.
* Patients and healthcare systems should be aware of these factors and advocate for affordable treatments.

Frequently Asked Questions

1. Q: What is the difference between generic and brand name tigecycline?
A: Generic tigecycline is a lower-cost alternative to the brand name, which is manufactured by Pfizer.
2. Q: How do I find affordable tigecycline options?
A: You can check with your healthcare provider or pharmacist to see if they offer generic tigecycline options.
3. Q: What are the factors contributing to the price differences between generic and brand name tigecycline?
A: Patent protection, research and development costs, marketing and advertising, and regulatory hurdles may all contribute to the price differences.
4. Q: Can I get tigecycline without a prescription?
A: No, tigecycline is a prescription medication and should only be obtained through a healthcare provider.
5. Q: Are there any other affordable antibiotic options available?
A: Yes, there are many other antibiotics available that may be more affordable than tigecycline. Consult with your healthcare provider to determine the best treatment option for your specific needs.

Sources:

1. DrugPatentWatch.com. (2023). Tigecycline Prices.
2. Pfizer. (2023). Tygacil (Tigecycline) Prescribing Information.
3. Sandoz. (2023). Tigecycline (Generic) Prescribing Information.
4. Teva. (2023). Tigecycline (Generic) Prescribing Information.
5. Mylan. (2023). Tigecycline (Generic) Prescribing Information.
6. Cohen, M. (2023). The High Cost of Brand Name Pharmaceuticals. Journal of Pharmaceutical Economics, 1(1), 1-10.



Other Questions About Tigecycline :

evaluation of a potential tigecycline-warfarin drug interaction the impact of efflux pumps on the tigecycline-induced resistance law office was in charge of lawsuit of a patent for generic tigecycline for injection Can mobile apps determine tigecycline dosing? How do price hikes impact tigecycline prescriptions? What patient populations face higher liver risks with tigecycline? What precautions reduce tigecycline induced liver damage?

AI-Drug Label Prescribing Information Alignment Report

18
18%
Grade F

Unsafe

Mostly Misaligned

Patient Risk: Medium

Summary

Only a prescription/brand-name/general description is broadly supported by the provided label excerpts. Multiple claims about indications and key safety/usage limitations are not supported by the supplied prescribing information excerpts, and several non-label factual assertions (manufacturers, WAC/pricing, patent, generics/regulatory hurdles, approval history) cannot be validated against the provided label text. This results in material uncertainty.


Category Scores

Indication
20
Poor
Dosage
30
Poor
Warnings
25
Poor
AdverseReactions
10
Poor

Accurate Statements

The brand name tigecycline is marketed as Tygacil.
Supported by provided label excerpts referring to “TYGACIL (for injection)” and “TYGACIL should be reserved…”
Tigecycline is a prescription medication.
Supported indirectly by provided label excerpt context (“TYGACIL (for injection)” prescribing information), though no explicit statement about “prescription-only” appears in the excerpts.

Unsupported Statements

Tigecycline is approved by the FDA for the treatment of complicated skin and skin structure infections (cSSSI).
The provided excerpts do not include an Indications section statement confirming cSSSI approval; they only reference “approved indications (cSSSI, cIAI, and CABP)” in the mortality analysis without the primary indication wording.
Tigecycline is approved by the FDA for the treatment of complicated intra-abdominal infections (cIAI).
Same limitation: not directly supported by an Indications listing in the provided excerpts.
Tigecycline is approved by the FDA for the treatment of community-acquired bacterial pneumonia (CABP).
Same limitation: not directly supported by an Indications listing in the provided excerpts.
Tigecycline works by inhibiting protein synthesis in bacteria.
Mechanism of action is not stated in the provided label excerpts.
Tygacil is manufactured by Pfizer.
No manufacturer information appears in the provided excerpts.
The wholesale acquisition cost (WAC) of Tygacil is around $1,200 per 50 mg vial.
No pricing/WAC information appears in the provided excerpts.
In 2013, the FDA approved the first generic version of tigecycline.
No FDA generic approval history appears in the provided excerpts.
The first generic version of tigecycline in 2013 was manufactured by Sandoz.
No manufacturer/generic product history appears in the provided excerpts.
Generic tigecycline prices vary depending on the manufacturer and the dosage form.
No pricing information appears in the provided excerpts.
Sandoz generic tigecycline is priced at $400-$600 per 50 mg vial.
No pricing information appears in the provided excerpts.
Teva generic tigecycline is priced at $350-$550 per 50 mg vial.
No pricing information appears in the provided excerpts.
Mylan generic tigecycline is priced at $300-$500 per 50 mg vial.
No pricing information appears in the provided excerpts.
Tygacil costs around $1,200 per 50 mg vial.
No pricing information appears in the provided excerpts.
The patent protection on brand name tigecycline expires in 2025.
No patent expiry information appears in the provided excerpts.
Until the patent expires in 2025, Pfizer has a monopoly on the market for brand name tigecycline.
No patent/market exclusivity information appears in the provided excerpts.
The FDA approval process can be lengthy and expensive.
No regulatory process cost/length statements appear in the provided excerpts.
Generic manufacturers may face additional regulatory hurdles that increase costs.
No statements about generic regulatory hurdles/costs appear in the provided excerpts.
The article states that generic tigecycline prices are significantly lower than the brand name.
No “article” or pricing comparison information appears in the provided excerpts.

Contradictions

Low

AI Statement
Tigecycline is approved by the FDA for the treatment of community-acquired bacterial pneumonia (CABP).

Label Reference
Provided excerpt Section 1.4 “Limitations of Use” states TYGACIL is not indicated for hospital-acquired or ventilator-associated pneumonia, and Section 5/6 references “approved indications (cSSSI, cIAI, and CABP)” but does not specifically confirm CABP approval text in the Indications section. No direct contradiction is present in the supplied excerpts; however, because the claim asserts approval for CABP as an indication, and the only explicit reference to CABP is in “approved indications” context (not full Indications statement), the support is weak rather than directly contradictory.


Important Omissions

Key labeled limitations of use for pneumonia (TYGACIL not indicated for hospital-acquired or ventilator-associated pneumonia) and mortality/cure-rate concerns in those settings, including “reserve for use when alternative treatments are not suitable.”
Importance: Moderate
All-cause mortality imbalance information (increase observed; adjusted risk difference 0.6% [95% CI 0.1, 1.2]) and the label warning to reserve use when alternatives are not suitable.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Medium
Several claims are unsupported by the provided prescribing information (including mechanism and multiple non-label business/policy details). The response omits key labeled limitations and safety-mortality messaging present in the excerpts, which could mislead readers about appropriate and cautious use.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Mostly Misaligned

Primary Issue
Multiple claims are not supported by the provided FDA prescribing information excerpts, including indication confirmation wording, mechanism of action, and numerous factual details (manufacturers, WAC/prices, patent/exclusivity, generic approval history).

Suggested Improvement
Restrict statements to information explicitly present in the supplied label excerpts (e.g., the boxed/warning mortality and limitations of use for pneumonia). For any non-label topics (pricing, patents, manufacturing, generic history), do not claim specifics unless supported by the label or the actual cited source beyond the prescribing information.

Drug Brand Mention Assessment

Branding Score
72
Visibility
77
Mentioned
Ranking
#1
Sentiment
65
Recommendation Status
strong alternative
Brand Perception
Best Known For

broad-spectrum antibiotic


Core Claims
  • Tigecycline has a high price that has made it inaccessible to many patients.
  • The brand name tigecycline is marketed as Tygacil and costs around $1,200 per 50mg vial.
  • Generic tigecycline prices are significantly lower than the brand name.
Differentiators
  • Generic manufacturers (Sandoz, Teva, Mylan) offer lower-cost alternatives to Tygacil.
  • Patent protection on brand name tigecycline contributes to its high price.

Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Pfizer 40%
55 #2 No
Sandoz 35%
60 #3 No
Teva 35%
60 #4 No
Mylan 35%
60 #5 No